企業プロフィール
Assertio 株価・ニュース・カタリスト
- ティッカー:
- ASRT
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
23.50 USD (+0.13%)
終値
最終更新: 2026年6月15日
152M USD
時価総額
株価変動の要因
ASRT の終値変動に関する情報は現在取得できません。
企業概要
Specialty Pharmaceutical Company
Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care. The company has assembled its portfolio through acquisitions and licensing transactions and operates commercial, market-access, trade, and distribution capabilities.
Rolvedon Oncology Franchise
Rolvedon, or eflapegrastim-xnst, is a long-acting granulocyte colony-stimulating factor used to reduce the incidence of infection manifested by febrile neutropenia in adults receiving myelosuppressive anticancer therapy. It is the company's lead product and is promoted to both hospital systems and community oncology practices.
Sympazan Neurology Product
Sympazan is an oral film formulation of clobazam used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients aged two years and older. The film adheres to the tongue and can serve patients who have difficulty swallowing conventional tablets or liquids.
Hospital and Pain Products
The remaining marketed portfolio includes INDOCIN formulations, SPRIX ketorolac nasal spray, and CAMBIA diclofenac oral solution. These products address hospital, acute-pain, migraine, and inflammatory-care settings, although they are less central to the company's current oncology-focused strategy.
Acquisition-Led Commercial Model
Assertio seeks approved or late-stage products that can be supported through its existing infrastructure. Centralized commercialization and portfolio integration allow the company to manage products across multiple specialty channels without operating a broad internal research platform.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。